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1. Introduction 
Fanconi anemia (FA) was first described in 1927 by the Swiss pediatrician Guido Fanconi in 
a family with five children, three of which had various physical abnormalities and 
hematological defects, in a condition that resembled pernicious anemia [1]. In all the three 
children the disease was manifested between ages of five to seven years old and had fatal 
consequences. Studies in peripheral blood cells from these and other patients with the same 
symptoms made Guido Fanconi to realize that the disorder affected all the hematopoietic 
lineages, not only erythropoiesis, and that these alterations were usually the main cause of 
mortality (See review in [2]). From the beginning of his studies, he thought that this disease 
was too complex to be caused by mutations in one single gene, but neither he, nor the rest of 
the research community could imagine at that time that mutations in at least fourteen 
different genes, currently known as FA genes, could account for the same disease. The 
description of the chromosomal instability of FA cells as a hallmark of the disease in 1964[3] 
focused the etiology of the disease as a DNA repair failure, but it was almost forty years 
later when this idea was confirmed. 
In this chapter we will make an overview of the implications of the FA pathway in DNA 
repair and cell survival, and discuss the advances, limitations and perspectives of the 
therapeutic approaches used for the treatment of the most severe problem that takes place in 
FA patients, the bone marrow failure (BMF).  
2. Fanconi anemia proteins form a complex pathway involved in the repair of 
DNA inter-strand cross-links 
Mutations in at least 14 genes have been associated with FA. Patients with biallelic 
mutations in any of these FA genes (except in FANCB, which is X-linked) are assigned to 
different complementation groups (Table 1). The identification of the first FA 
complementation group was conducted by the fusion of cell lines generated from different 
FA patients[4]. The first FA gene, FANCC, was then identified by the transfection of cells 
from a FA patient with a cDNA expression library, followed by their exposure to mitomycin 
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C (MMC), a DNA cross-linking drug that is extremely toxic and generates specific 
chromosomal instability in FA cells[5]. Only those cells complemented with FANCC grew 
after MMC exposure, allowing the identification of the defective gene in these patients. 
Similar approaches, together with positional cloning and linkage analysis, allowed the 
identification of other protein members of the so called “FA core complex”, which included 
FANCA, FANCG, FANCF and FANCE[6-10]. Although the description of FANCD2[11] and 
its activation by monoubiquitination after DNA damage linked FA with DNA repair, the 
confirmation of the involvement of the FA pathway in DNA repair and its link to 
homologous recombination occurred in 2002, when BRCA2 was identified as the FANCD1 
gene[12]. After the discovery of BRCA2 as a FA gene, several other FA genes were 
described, initially FANCL, containing the ubitiquitin ligase activity of the complex [13]and 
later on, FANCB; the only FA gene linked to the X chromosome[14]. The description of 
FANCJ (BRIP1)[15-17], PALB2[18] and RAD51C (not formally assigned yet as a FA gene)[19, 
20] together with the previously described BRCA2, definitively linked the FA/BRCA 
pathway with increased cancer susceptibility[19, 21-24]. In subsequent studies FANCI [25-
27] was found to be the partner of FANCD2. Additionally, the finding that FANCM[28] can 
interact with DNA, and the observation that FANCP (SLX4) had endonuclease activity, is 
allowing to unravel the role of the FA/BRCA pathway in the repair of DNA interstrand 
cross-links (ICLs) during replication [29](Table 1).  
Interstrand cross-linking drugs covalently bind both strands of the DNA helix, blocking the 
DNA replication and transcription. As a consequence of stalled replication produced by 
ICLs or at S-phase entry, the FA pathway is activated (See review in [29]). Although the 
exact role of FA proteins in the repair of ICLs is not clear yet, it is known that they work 
together in a complex network, where the key event is the monoubiquitination of 
FANCD2[30] and FANCI [25-27] (D2-I complex). This monoubiquitination requires the 
presence of the FA core complex, currently known to be formed by FANCA, FANCB, 
FANCC, FANCE, FANCF, FANCG, FANCL and FANCM[31], together with other FA 
associated proteins(FAAP; see Figure 1). The description of the last members of the 
FA/BRCA pathway, particularly FANCM, FAN1 (associated nuclease, with no mutations 
still found in FA patients)[32-35] and FANCP (SLX4)[36, 37] has added new critical elements 
in this intriguing pathway.  
After the generation of an ICL in the DNA, the progression of the DNA replication fork is 
stalled, and this activates the FA core complex and ATR. The first protein from FA pathway 
that seems to initiate DNA repair is FANCM. This protein, thanks to its translocase activity 
[28], together with FAAP24 and MHF1/2[29], moves along the DNA to sense the stalled 
replication fork[38], facilitating the translocation and anchoring the rest of the FA core 
complex to damaged DNA. In this way, the FA core complex can monoubiquitinate 
FANCD2/I, inducing the replication fork pause and the incision/unhooking of the ICL, 
facilitating the translesion synthesis and finally the HR machinery required for the repair of 
the DNA damage [39, 40]. Once the D2-I complex is monoubiquitinated, another FA protein 
- FAN1 - is also recruited to sites of DNA damage, where all these proteins form large 
nuclear foci. The endonuclease activity of FAN1 suggests that this protein could also pair 
with MUS81-EME1 to unhook the ICL[32, 35, 40] necessary for DNA repair. In this step, the 
endonuclease XPF-ERCC1, whose activity is coordinated by the last described member of 
the FA family SLX4 (FANCP[36, 37]), probably also plays an important role in the repair of 
the DNA damage (See Figure 1). 
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* FANCO/RAD51C is not formally defined as a FA gene. NLS; nuclear localization signals. HR; 
Homologous recombination 
Table 1. Main characteristics of the Fanconi anemia genes and their proteins.  
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Fig. 1. Description of the four essential steps in the repair of DNA interstrand cross-links of 
the FA/BRCA pathway (Adapted from Niedernhofer [39] , Kee et al.[29], Valeri et al. [41] 
and Cybulski and Howlett[42]). 
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3. Clinical features of Fanconi anemia 
Fanconi anemia is a rare autosomal recessive disease (except for FA-B which is X-linked), 
with an estimated frequency of 1-5 per 100,000 births. Although the presentation of the 
disease is very heterogeneous, around 70% of FA patients show physical anomalies, such as 
skeletal abnormalities, including radial hypoplasia, short stature and microphtalmia. Most 
FA patients present hypo or hyperpigmentation of the skin, showing the characteristic café 
au lait spots, and with a lower frequency, cardiac, renal, gastrointestinal and other organ 
malformations [43]. The most common feature of the disease is the bone marrow failure 
(BMF), which is manifested at a median age of 8 years, being the primary cause of morbidity 
and mortality in FA patients[44]. Clinical data from the International Fanconi anemia 
Registry (IFAR) and the German Fanconi anemia Registry (GEFA) have shown that virtually 
all FA patients would develop BMF by the age of 40 years[45, 46]. At birth, the blood counts 
are usually normal, macrocytosis usually being the first symptom detected in these patients, 
followed by thrombocytopenia and neutropenia. Pancytopenia is generally presented 
between 5 and 10 years of age. The German and American studies showed that the use of a 
defined abnormality score, based on the analysis of five different congenital abnormalities, 
can significantly predict the development of the BMF in FA patients[46, 47]. 
In addition to the BMF, the incidence of cancer in FA patients is also markedly increased 
compared to the normal population, the incidence of myelodisplasia (MDS) or acute 
myeloid leukemia (AML) being 33% at the age of 40 years (more than eight hundred fold 
increased incidence compared to a healthy population). Reports from the IFAR and GEFA 
have also shown that FA patients are at extraordinary risk of developing specific solid 
tumors, such as head and neck squamous cell carcinomas (HN-SCCs; with several hundred 
fold increased frequency), esophagus SCCs (several thousand fold increase) and vulvar 
cancer in women (also several thousand fold increase)[46, 48, 49].GEFA also observed an 
increase in breast and brain tumors, while the North American study observed an increased 
incidence of cervical,ostesarcoma and liver tumors [46].  
Myelodisplasia is often presented as a refractory cytopenia with multilineage dysplasia, 
with or without excess of blasts[49]. Acute myeloid leukemia can be diagnosed primarily or 
after a MDS phase, with an increasing fraction of blast cells in the BM[50]. The high selective 
pressure during their teens or early adulthood is probably involved in the development of 
clonal MDS and AML. The most common abnormalities found in FA patients with 
MDS/AML are gains of chromosome 1q, monosomy 7, gains of 3q (where EVI1 is included) 
[44, 49-51], and abnormalities in RUNX1/AML1 gene at chromosome 21q[50]. Results by 
Quentin et al also suggest a model of multi-step oncogenesis progression in the BM of FA 
patients, in which 1q+ (which can be found in the aplastic anemia form of the disease) 
would possibly constitute the initiating event, while the 3q+, -7/7q and RUNX1 
abnormalities would lead to high grade MDS or AML. In this model 1q+ might clonally 
rescue the BMF of FA patients, but would not protect against progression towards MDS and 
leukemia[50]. 
A remarkable aspect concerning the clinical symptoms of the disease is the observation that 
some of FA patients can undergo somatic mosaicism by means of a spontaneous reverse 
mutation or mitotic recombination in one of the FA pathogenic mutations in particular 
somatic cells[52-54]. If such a reversion occurs in a hematopoietic progenitor or stem cell 
(HSC), it may confer a proliferation advantage to the reverted cell, leading to the recovery of 
the BMF in the patient[52-55].  
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A recent paper described for the first time a characteristic phenotype in a number of FA 
patients who showed two of the FA hallmark features (high number of chromosomal 
aberrations after DNA damage and absence of FANCD2 monoubiquitination), compatible 
with normalized hematological counts[56]. Remarkably, blood cells from these patients did 
not show the FA characteristic G2/M cell cycle arrest after exposure to DNA cross-
linkers[56]. Moreover, in contrast to mosaic FA patients, no reversion in the pathogenic 
mutations occurred in this new group of FA patients. Based on the above observations, a 
phenomenon defined as attenuation of the phenotype was described in FA[56]. Attenuation 
was associated with almost normal blood cell counts, and in some cases with development 
of MDS or AML. This process was accompanied by clonal hematopoiesis, implying that all 
peripheral blood cells derive from a single progenitor cell, in which a molecular event 
reducing CHK1 expression took place, resulting in the attenuated G2 arrest. The conclusions 
of this work have important implications in the management of FA patients because patients 
with this phenotype, although having essentially normal blood cell counts, should be 
followed closely to prevent the development of MDS or AML. Additionally, this study 
offers new explanations that could account for differences in the severity of the disease 
between FA siblings with the same mutation. Another important study has recently shown 
that FA proteins also play a role in mitosis, since FANCD2, FANCI and FANCM are 
localized to the extremities of ultrafine DNA bridges (UFBs), which link sister chromatids 
during cell division. FA cells show increase number of UFBs that may inhibit cytokinesis, 
leading to binucleated or multinucleated cells, a phenomenon that could account for the 
increased apoptosis and thus, also contribute to BMF [57, 58]. 
4. Main phenotypic characteristics of Fanconi anemia cells 
FA cells are hypersensitive to ICL agents such as mitomycin C (MMC) and diepoxibutane 
(DEB). Additionally, these drugs specifically induce a high number of chromosomal 
aberrations in FA cells[59, 60], thus constituting a hallmark for the diagnosis of FA 
patients[60, 61]. Although normal cells exposed to DNA cross-linkers develop a transient 
accumulation in the G2/M phase of the cell cycle, the defective ability of FA cells to repair 
the DNA damage leads to a very significant accumulation of these cells in G2/M after 
exposure to ICLs[62]. This property has been also used for the diagnosis of FA patients, 
particularly in skin fibroblasts for the characterization of FA mosaic patients in which no 
obvious phenotypic markers may be apparent in their peripheral blood cells[63, 64]. 
FA cells are also characterized by their hypersensitivity to ambient oxygen conditions [65-
67], manifested by a poor ex vivo growth and clonogenic capacity. This impaired growth 
properties of FA cells can be significantly restored when the incubation atmosphere is 
changed to hypoxic conditions (<5% of oxygen)[67], mimicking the low oxygen 
concentrations present in most tissues, including the BM niche[68, 69]. 
FA cells also show an increased apoptotic predisposition, something that may account for 
the BMF of these patients and for the development of malformations during embryonic 
development. One of the biochemical pathways involved in the increased apoptosis of FA 
cells is related to the over-production of cytokines such as TNFα and interferon-γ [70, 71]; an 
observation that has been confirmed in BM from FA patients[72].  
FA patient hematopoietic progenitor cells have also shown a defective adhesion and homing 
activities, associated with an aberrant regulation of Cdc42 activity[73].  
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5. Identification of complementation groups in Fanconi anemia patients 
As described before, fourteen different FA genes have been described so far, whose 
mutations account for the different FA complementation groups already identified (Table 1). 
However, there is still a number of patients with clinical symptoms of FA without mutations 
in any of the 14 FA genes, suggesting that more FA genes will be added to this long list. The 
identification of the FA complementation group (FA subtyping) in a patient has several 
advantages in the management of the disease. In this respect FA subtyping 1) confirms the 
FA diagnosis; 2) facilitates the identification of pathogenic mutations in FA genes, 3) allows 
to investigate relationships between the phenotype and the genotype in the patients, and 4) 
it is required for a potential future treatment of the patient by gene therapy. 
Once a patient is diagnosed with FA, several alternatives have been used for FA subtyping. 
Because of the technical difficulties of the cell fusion approaches initially developed by 
Buschwald[4, 5], Hanenberg et al. in 2002 developed a new strategy based on genetic 
complementation strategies with retroviral vectors harboring the different FA genes[74]. 
This strategy, combined with Western blot analyses, principally of the monoubiquitinated 
and non ubiquitinated forms of FANCD2 (to detect if the mutation is upstream  
or downstream FANCD2 monoubiquitination), and also with the analysis of foci of nuclear 
proteins, has allowed the assignment of FA patients to the different complementation 
groups[75]. Sequencing has also been used [76]however, the large number and complexity 
of some FA genes and their mutations, together with the necessity of verifying  
the pathogenicity of each new mutation, implies that subtyping of patients with FA  
by mutational analysis is often time consuming and laborious [75]. Nevertheless, sequencing 
combined with genetic complementation strategies can be useful to deeply characterize  
FA patients. 
6. Current treatments of the bone marrow failure in Fanconi anemia patients 
As discussed above, the BMF is the main cause of mortality in FA patients. Many of the 
treatments of the BMF are palliative and directed to maintain acceptable numbers of 
peripheral blood cells. The use of androgens, in some cases combined with corticoids, 
constitute one of the most common treatments of FA patients in early stages of the disease, 
when a residual endogenous hematopoiesis remains[43, 77]. However, not all the patients 
respond to this treatment and, in most cases the response is slow, transient and normally 
limited to the red blood cells. Although a longer survival has been reported in patients who 
have been treated with androgens, in comparison with those who have not (20 years vs 14 
years) [77], it has been reported that their use might constitute an adverse predictor when 
hematopoietic cell transplantation (HCT) is required [78]. Additionally, side effects such as 
liver tumors[48, 79] and masculinization may occur when androgens are used[80].  
The use of growth factors to activate specific hematopoietic lineages has been also used in 
FA patients[81, 82], although generally with a limited success due to the transient benefit 
[82] and risks of leukemia due to the activation of potential pre-leukemic clones already 
present in the patient[83].  
So far, the only curative treatment capable of restoring the hematopoiesis of FA patients in 
the long-term is allogenic HCT. Many of the obstacles initially found for the HCT of FA 
patients have been overcome nowadays. The hypersensitivity of FA patients to conditioning 
regimens was a limiting factor for the success of the first HCTs in FA patients. However, 
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conditioning is necessary to eliminate the endogenous hematopoiesis and allow the 
engraftment of donor cells. In 1984, Gluckman et al. [84] developed the first successful 
conditioning regimen for FA patients consisting of a low dose of cyclophosphamide (CY) 
and a single dose of total body irradiation (TBI). Since then, many different protocols have 
been developed aiming to limit the radiation exposure in HCT preparative regimens[85], 
and thus to minimize risks of malignancies in the long-term[77]. As a result of these 
improvements, current HCTs from HLA(Human Leukocyte Antigen) identical siblings do 
not generally include irradiation in the conditioning. The use of mild conditioning regimens 
and the inclusion of fludarabine (FLU) (an antimetabolite with profound 
immunosuppressive effects) has, therefore, markedly improved the outcome of HCTs with 
HLA-matched grafts from related donors.  
Although the outcome of transplants from alternative donors in FA has also markedly 
improved in the last decade, the morbidity and mortality associated to these transplants is 
still significant[86]. Problems like graft failure, acute and chronic graft versus host disease 
(GVHD) and opportunistic infections are the major obstacles to address. Again, the 
inclusion of FLU and the use of T cell depletion (TCD) have significantly improved the 
efficacy of the transplant of FA patients from unrelated donors[87]. Recent clinical trials 
conducted in the University of Minnesota have shown the relevance of thymic shielding 
during irradiation with reduced doses of TBI to limit opportunistic infections, and thus to 
increase overall survivals after unrelated HCTs in FA patients[88]. Ideally, transplantation 
should be done previously to the development of a myelodysplasic syndrome or 
leukemia[88]. The success of HCTs in patients that already have developed any of these 
pathologies is limited in comparison to those who have not. The main risk associated with 
the HCT of these patients is that the low doses of radio/chemotherapy that must be used in 
FA patients might not be enough to destroy the endogenous leukemic cells, thus increasing 
the risk of future relapses [88].  
Traditionally the preferential source for the HCT for FA patients was BM or mobilized 
progenitors from peripheral blood (mPB). However, umbilical cord blood is nowadays also 
a good alternative for the transplantation of FA patients. This is not only the case for the 
HCT from HLA-identical siblings - in some instances derived from in vitro fertilization and 
preimplantation genetic diagnosis - but also from unrelated donors[89].  
7. Gene therapy as a new strategy for the treatment of Fanconi anemia 
Hematopoietic gene therapy, defined as the HCT of genetically corrected autologous HSCs, 
is considered a good alternative to allogenic HCT in FA. This strategy would avoid GVHD 
and limit, at least partially, the side effects associated to severe chemo/radiotherapy and 
immunosupression (See review in [90]).  
The previous observation that a number of mosaic FA patients (those who have reverted a 
pathogenic mutation in a HSC) could progressively improve their hematological status[52-
55] opened the possibility of rescuing the BMF of FA patients after the infusion of gene-
corrected HSCs, even in the absence of conditioning. As it is the case with HSCs that have 
reverted a pathogenic mutation, it is expected that ex vivo corrected FA HSCs may also 
develop a proliferation advantage over uncorrected cells, thus restoring progressively 
hematopoietic system of the patient. 
To allow the stable integration of the transgene in the HSCs genome, gamma-retroviral 
vectors (RVs) have been the most frequently used vectors in clinical gene therapy protocols 
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[90, 91]. The principle of most of these protocols was based on the purification of CD34+ 
cells, either from BM or mPB, followed by the transduction with the therapeutic vector, and 
the re-infusion of the transduced cells in the patient, either pre-conditioned or not[91-94]. 
Two different gene therapy trials have been already conducted in FA. The first one was 
developed by Liu and colleagues in FA-C patients [95] and the second one by Kelly and 
colleagues in FA-A patients [96]. Both protocols used similar conditions to those previously 
used for the gene therapy of other monogenic diseases, such as X1-SCID. Essentially, in both 
protocols in vitro pre-stimulated CD34+ cells were transduced with RVs for three or four 
days in culture, and thereafter infused into non conditioned patients. In contrast to the 
results observed in X1-SCID patients, none of these protocols improved the clinical status of 
FA patients, indicating the necessity of improving the therapeutic vector and/or the 
manipulation of the target cells. 
8. Towards the development of improved protocols of Fanconi anemia gene 
therapy  
8.1 Lessons from Fanconi anemia mouse models 
Mouse models represent an invaluable tool for improving the understanding of the 
mechanisms responsible of different pathologies, and also for developing new therapies 
with improved efficacy and reduced side effects. In the case of FA, where intrinsic 
difficulties exist to engraft inmunodeficient mice with BM from FA patients, the relevance of 
mouse models is even higher.  
Different FA mouse models with disruptions in FA genes such as Fanca[97, 98], Fancc[99, 
100], Fancd1(Brca2)[101], Fancd2[102], Fancg[103], Fancm[104] and more recently Fancp 
(Slx4)[105] have been generated (See Table 2). Additionally, a FA mouse model based on the 
deletion of Usp1 (the enzyme responsible for FANCD2 deubiquitination) has been 
described[106]. This gene, however, is not currently considered a FA gene since no FA 
patients have been so far identified with Usp1mutations.  
Although all FA mouse models are characterized by their hypersensitivity to DNA-cross-
linking agents and in some instances to cytokines such as TNFα and IFN( (See Table 2), the 
severe BMF that takes place in FA patients is far from being reproduced in these models. In 
fact, only the recently developed mouse model of FA-P (Btbd12-/- mice) is prone to develop 
marked blood cytopenias, reflected by a reduction in white blood cells (WBCs) and platelets 
in a significant number of animals[105] (Table 2).  
Aiming to generate FA mouse models that resemble more closely the disease observed in 
FA patients, double knock-outs have been also generated. Among these mouse models, only 
the double knock-out Fancc-/-/Fancg-/- mice [107] and the Fancc-/-/Sod1-/- mice showed 
evidences of BMF [108].  
Significantly, although some FA mouse models are prone to develop tumors (i.e. FA-D1, FA-
D2, FA-M), AML is not spontaneously generated in the FA mouse models generated so far. 
Studies conducted in Fancc-/- mice have shown, however, that the ex vivo culture and/or 
incubation of Fancc-/- BM cells with TNF-α, whose expression is significantly increased in FA 
patients, induces leukemic clonal evolution after transplantation [109, 110], suggesting that 
leukemia development in FA patients could be at least partially related to the deregulated 
expression of this cytokine. 
Fanca-/- as well as Fancc-/- mice, and also mice with a hypomorphic mutation in Brca2/Fancd1 
(FA-D1 mice) constitute the FA mouse models more frequently used both to understand the 
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role of FA genes in HSCs functionality, and also to evaluate the preclinical efficacy of new 
therapies in FA. Defects in the HSCs have been observed in all tested FA mouse models, not 
only in terms of clonogenic potential, but also regarding the engrafting ability and 
repopulating properties of these cells (see Table 2). Although no aplastic anemia was 
observed in FA-D1 mice, this mouse model showed a more severe hematopoietic phenotype 
compared to other models with mutations in FA genes upstream in the FA/BRCA 
pathway[111]. In this respect, results from our laboratory showed a defective function in the 
repopulating potential of endogenous FA-D1 HSCs in their own natural microenvironment. 
This was demonstrated by the observation that BM cells from WT animals could repopulate 
in the long-term the hematopoietic tissues of FA-D1 unconditioned recipients [111]. This 
contrasts with studies conducted in other FA mouse models where only after the treatment 
with IFNγ [112, 113] or DNA damaging drugs, wild-type BM cells could be engrafted in FA 
recipients (Table 2). 
In the field of gene therapy, it was shown for the first time in Fancc-/- mice that the retroviral-
mediated expression of Fancc corrects the defective repopulation ability of FA HSCs[114]. 
Similar conclusions were obtained in different FA mouse models using RVs, Lentiviral and 
also Foamyviral vectors (LVs and FVs; Table 1). Significantly, Li et al. showed that the ex vivo 
culture of Fancc-/- HSCs increases apoptosis and promotes the development of clonal 
aberrations[109]. Studies conducted with Fanca-/- and Fancc-/- mice showed, on the other 
hand, that rapid transductions with LVs or FVs markedly improved the repopulating 
properties of the HSCs (Table 2). Taken together, these studies suggest the convenience of 
using similar short-transduction protocols in human FA gene therapy.  
Working with the FA-D1 mouse model, our group showed that the infusion of LV-
transduced cells in mice pre-treated with a mild conditioning results in a progressive 
increase in the proportion of genetically-corrected cells, in the absence of any selection 
treatment. This is in contrast to data obtained in other FA mouse models, where exposures 
to cytokines or DNA damaging agents were required (Table 2). Moreover, our data showed 
that in the long term after transplantation, most of the hematopoietic cells of recipient FA-
D1 mice were resistant to otherwise cyototoxic doses of MMC and became genetically stable 
[115], suggesting that a similar proliferation advantage of ex vivo corrected HSCs may occur 
in FA clinical trials.  
8.2 Lessons from in vitro studies conducted with bone marrow samples from  
FA patients 
Based on the current knowledge on the biology of FA cells, it is now clear that marked 
differences distinguish FA HSCs from HSCs successfully treated with gene therapy (i.e. X1-
SCID HSCs). In this respect, it has been already shown that in the case of FA HSCs, in vitro 
incubation induces apoptosis and genomic instability [109, 116, 135]. Therefore, it is now 
considered that short transduction strategies would improve the possibilities of engrafting 
FA patients with genetically corrected cells, as it has been already shown in FA mouse 
models [119, 125]. 
Because of the limited number of hematopoietic progenitors and HSCs present in the BM of 
FA patients [136], we hypothesized that these precursor cells would be actively cycling in 
the patient and therefore, directly susceptible to transduction with RVs without further in 
vitro stimulation. Consistent with this hypothesis, our studies showed that hematopoietic 
progenitors from FA patients can be efficiently transduced by Gibbon Ape Leukemia Virus 
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(GALV)-packaged RVs in protocols that lasted only 12-24 h [136]. Whether or not the most 
primitive HSCs were also efficiently transduced in these protocols is, however, unknown 
due to current limitations to engraft immunodeficient animals with BM from FA patients.  
 
 
BMF: Bone marrow failure; CTK: Cytokines; CFC: colony forming cell; Chemo: chemotherapy; CPA: 
cyclophosfamide; CRA: Competitive repopulation ability; FV: foamyviral vector; HSC: hematopoietic 
stem cell; IR: Ionizing radiation; LV: lentiviral vector; MMC: Mitomycin C; RV: Retroviral vector 
Table 2. Principal characteristics of the hematopoietic system of FA mouse models and 
results from ex vivo HSC gene therapy.  
Experimental studies [137, 138] and more recently also human trials[139, 140] have 
demonstrated that LVs currently constitute the most efficient clinical vectors for stably 
transducing HSCs after very short transduction periods. Additional studies have shown that 
these vectors facilitate the stable expression of the transgene in vivo, while transgene 
inactivation has been frequently reported in RVs[137]. Finally, but not less importantly, LVs 
have shown improved safety properties, compared to the RVs already used in human gene 
therapy [141-145].  
Concerning the level of expression that is required for inducing a therapeutic effect in FA 
cells, we have recently shown in FA-A and FA-D2 cells that a weak expression of FA genes, 
at least FANCA and FANCD2, is sufficient to revert the FA phenotype of hematopoietic cells 
([146],[147] and unpublished data). Because FA-A is the most frequent FA complementation 
group [75, 148] our group [147], as well as Hans-Peter Kiem group[149] have proposed 
independently the same LV construct for the gene therapy of FA patients. In this vector 
FANCA expression is driven by the phosphoglycerate kinase (PGK) promoter and stabilized 
by a mutated version of the posttranscriptional regulatory element (WPRE) [147, 149](see 
Figure 2). 
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Fig. 2. Illustration of the FANCA-LV proposed independently by González-Murillo et al 
[147] and Becker et al [149] for the gene therapy of FA-A patients.  
Studies conducted with BM samples from FA patients have also shown that FA progenitor 
cells are highly sensitive to cytokines such as TNF-α or IFN- γ and also to reactive oxygen 
species (ROS) [121, 150-154]. Thereafter it was shown that the use of ex vivo manipulation 
conditions that limit the oxidative damage (hypoxia or inclusion of N-acetyl-cysteine) 
improved the growth of FA progenitor cells[149, 155]. Similar observations were obtained 
when TNF-α฀was specifically inhibited with antibodies[72, 136]. Based on these observations 
and with the aim of improving the repopulation potential of genetically corrected HSCs, 
many of the experimental protocols aiming the genetic correction of FA HSCs use hypoxia 
and antibody-mediated inhibition of TNF-α[149, 155]. 
Concerning the ideal target population to be transduced in FA gene therapy trials, we 
reasoned that, if possible, the transduction of total BM would be the preferential option[155]. 
This suggestion derives from the fact that in FA every type of HSC, and also of accessory 
BM cell, would be directly affected by the genetic defect. Therefore, the genetic correction of 
each of these populations might be useful for the engraftment of the patient. Using GALV-
TR (modified GALV envelope) packaged LVs carrying FANCA and/or EGFP, we 
demonstrated the possibility of efficiently transducing hematopoietic and mesenchymal 
progenitor cells in FA BM samples subjected to a very simple erythrocyte’s depletion[155]. 
Although our data showed that, in contrast to LVs packaged with the G-protein from 
Vesicular Stomatitis Virus (VSV-G), GALV-TR packaged LVs can efficiently transduce FA 
BM samples at low multiplicities of infection (around 1-3 infective units/cell), there are still 
limitations in the production of GMP GALV-TR LVs at high titers. Because high MOIs 
(Multiplicity of infection) of VSV-G LVs produced in conditions approved for clinical use 
(GMP) are required to achieve efficient transductions, purified CD34+ or CD133+ cells 
currently constitute the preferential populations to be used in the next FA gene therapy 
protocols[156].  
9. Perspectives for the future gene therapy of Fanconi anemia patients 
The discovery by S. Yamanaka that the transfer of a few transcription factors can reprogram 
adult somatic cells and generate induced pluripotential cells (iPS cells) [157] has opened new 
perspectives for the cell and gene therapy of different diseases, particularly in FA. The 
collaborative study conducted between our group and J.C. Izpisua-Belmonte and J. Surralles 
groups demonstrated for the first time the possibility of generating disease-free hematopoietic 
progenitors from genetically corrected fibroblasts from patients with a monogenic disease, 
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specifically FA patients[158, 159]. Although the technology related to iPS cell generation 
should be further improved both in terms of efficiency and safety, these strategies have 
opened an unpredicted applicability in the management of genetic diseases like FA. 
10. Concluding remarks  
Since the description of the first FA patient by Guido Fanconi in 1927, an extraordinary 
advance in the understanding of the mechanisms accounting for the disease has occurred. 
Although more work is still required to elucidate the interactions between the FA/BRCA 
pathway with the different mechanisms of DNA repair, the relevance of this pathway in the 
repair of different insults to the DNA is now clear, accounting for the involvement of the 
FA/BRCA pathway in hereditary and also acquired cancer. Significant advances in the 
management of the hematopoietic syndromes that FA patients suffer have been produced 
within the last years, particularly in the field of hematopoietic transplantation. Thanks to these 
advantages, FA is nowadays not considered a restricted pediatric disease. New challenges 
have therefore emerged, particularly due to the necessity of developing improved therapies 
for syndromes that appear in adult FA patients, such as squamous cell carcinomas.  
As happened in other diseases, gene therapy was soon considered a good option for the 
treatment of the BMF in FA patients. Although intrinsic difficulties in the manipulation of 
FA HSCs have limited the success of FA gene therapy, new vectors and improved FA HSC 
manipulations have emerged from studies conducted with FA mouse models and with 
samples from FA patients. All these technical advances have opened new hopes for the 
application of gene therapy in FA.  
Finally, as it was the case with the clinical application of cord blood cells [160] or cells 
derived from siblings selected by pre-implantation genetic diagnosis[161, 162], FA is the first 
genetic disease where disease-free blood cells from non hematopoietic tissues, have been 
generated [158]. It is our hope that all these advances may have a translational clinical 
impact in our patients in the near future.  
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